Saltar al contenido

Jazz Pharmaceuticals plc (JAZZ) stock: revenue, earnings & dividend

Jazz Pharmaceuticals plc (JAZZ, Nasdaq): revenue, earnings, dividend and balance sheet from official SEC filings.

Stock screener JAZZ · Nasdaq Pharma & Biotech IE-

Key figures

Fiscal year
2025
Revenue
4.27 bn $
Revenue growth
4.9 %
Revenue growth 5y (p.a.)
12.5 %
Net income
-356.15 m $
Net margin
-8.4 %
Operating margin
-10.1 %
Earnings per share (diluted)
-5.84 $
Dividend per share
–
Payout ratio
–
Consecutive dividend years
–
Consecutive dividend raises
–
Dividend growth 5y (p.a.)
–
Total assets
11.7 bn $
Equity
4.32 bn $
Equity ratio
37 %
Return on equity
-8.3 %
Cash
1.39 bn $
Operating cash flow
1.36 bn $
Free cash flow
1.3 bn $
Shares outstanding
64,189,052

History

Revenue by fiscal year

2016 1.49 bn $
2017 1.62 bn $
2018 1.89 bn $
2019 2.16 bn $
2020 2.36 bn $
2021 3.09 bn $
2022 3.66 bn $
2023 3.83 bn $
2024 4.07 bn $
2025 4.27 bn $

Net income by fiscal year

2016 397 m $
2017 488 m $
2018 447 m $
2019 523 m $
2020 239 m $
2021 -329.67 m $
2022 -224.06 m $
2023 415 m $
2024 560 m $
2025 -356.15 m $
YearRevenueNet incomeEPSDividend per shareOperating cash flow
20254.27 bn $-356.15 m $-5.84 $–1.36 bn $
20244.07 bn $560 m $8.65 $–1.4 bn $
20233.83 bn $415 m $6.10 $–1.09 bn $
20223.66 bn $-224.06 m $-3.58 $–1.27 bn $
20213.09 bn $-329.67 m $-5.52 $–779 m $
20202.36 bn $239 m $4.22 $–900 m $
20192.16 bn $523 m $9.09 $–776 m $
20181.89 bn $447 m $7.30 $–799 m $
20171.62 bn $488 m $7.96 $–693 m $
20161.49 bn $397 m $6.41 $–592 m $

Data from XBRL filings at the SEC, processed automatically, no guarantee. Not investment advice. All filings at the SEC (EDGAR)